Skin pigmentation disease

Depigmentation therapy refers to medical treatments that remove skin pigmentation. Depigmentation therapy is used in someone that has widespread, but incomplete, vitiligo on the face and/or other sites, in an attempt to improve their appearance. The most commonly used depigmenting agent is monobenzyl ether of hydroquinone (MBEH). If the patient cannot tolerate MBEH, or if treatment fails, combination therapies or other treatments may be considered. Depigmentation therapy may be considered in the management of treatment resistant vitiligo affecting more than 50% of the body surface area or affecting cosmetically sensitive, exposed body sites.

  • monobenzyl ether of hydroquinone agent in vitiligo
  • strict sun protection
  • psychological and cultural issues
  • common and uncommon side effects
  • combination therapy
  • Diphencyprone, Imiquimod potential treatment

Related Conference of Skin pigmentation disease

November 17-18, 2025

8th International Dermatology Conference: Skin and Body

Paris, France
February 05-06, 2026

9th Annual Conference on Skin Cancer and Dermatology

Paris, France
May 07-08, 2026

9th World Cosmetic and Dermatology Congress

Paris, France
June 22-23, 2026

28th World Dermatology and Aesthetic Congress

London, UK
August 25-26, 2026

26th European Dermatology Congress

Paris, France

Skin pigmentation disease Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in